Integrated DNA Technologies opens new synthetic biology manufacturing facility in Coralville

Dedicated site provides growth runway for manufacturing of synthetic biology products to support growing demand

IDT synthetic biology facility
Integrated DNA Technologies' new synthetic biology manufacturing facility in Coralville. CREDIT INTEGRATED DNA TECHNOLOGIES

Global genomics solutions provider Integrated DNA Technologies (IDT) has announced the expansion of its synthetic biology operations with the opening of a new 25,000 square-foot-site in Coralville.

The two-story building will be dedicated to the manufacturing of IDT synthetic biology products. It will double IDT’s synthetic biology footprint and enable IDT to further enhance its gene synthesis portfolio with differentiated offerings, according to a May 29 release.

“The expansion of our synthetic biology manufacturing operations adds significant capacity for IDT and lays the foundation for the future growth of our synthetic biology product portfolio,” said IDT president Demaris Mills. “With this increased footprint, we will be introducing new product enhancements, which will include the launch of a rapid gene synthesis offering expected in late Q2. This investment provides IDT with a growth runway for its synthetic biology product portfolio and manufacturing arm to support the rapidly expanding global DNA synthesis market and related drug development activity.”

Located near IDT’s flagship U.S. headquarters, more than half of the 25,000 square-foot facility has been dedicated to synthetic biology lab spaces. Other areas include office and conference rooms, amenities, onsite dedicated support resources, and additional space for future expansion.

The new facility will include enhanced cold storage, facility and flow designed for lean manufacturing, and LED lighting and building automation systems to enable energy efficient building performance. The facility will be operational 24 hours a day, seven days a week.

The investment comes after IDT’s recent launch of a new custom vector onboarding tool to equip researchers with an easy-to-use solution that enables them to skip in-house cloning steps and move quickly into functional studies with 100% sequence-verified clonal DNA. The launch was the latest addition to IDT’s broad synthetic biology portfolio, comprised of gene and gene fragment offerings.

As a large-scale provider of synthetic DNA, IDT can make gene fragments between 125 bp to 3 kb, and custom genes from 25 bp to over 5 kb.

The expansion of IDT’s synthetic biology manufacturing facility marks the second facility completion for IDT within the last 12 months. In late 2023, IDT announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility, which commemorated its entrance into the therapeutics space.